Intravenous iron among cystic fibrosis patients

Journal of Cystic Fibrosis

Volumn 11, Issue 6, 2012, Pages 560-562

  Hoo, Z H ^a   Wildman, M J ^a  

^a NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN; FERRIC CARBOXYMALTOSE; HEMOGLOBIN; IRON;

ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; CELL VOLUME; CYSTIC FIBROSIS; DISEASE EXACERBATION; FORCED EXPIRATORY VOLUME; HUMAN; IRON DEFICIENCY; LETTER; LEUKOCYTE COUNT; LUNG DISEASE; PSEUDOMONAS AERUGINOSA;

ANEMIA, IRON-DEFICIENCY; CYSTIC FIBROSIS; FERRIC COMPOUNDS; HUMANS; HYPERSENSITIVITY; INFUSIONS, INTRAVENOUS; IRON; LUNG DISEASES; MALTOSE; RETROSPECTIVE STUDIES;

EID: 84869080368     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2012.05.002     Document Type: Letter

References (5)

1. Lyseng-Williamson K.A., Keating G.M. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs 2009, 69:739-756.
2. Vasil M.L., Ochsner U.A. The response of Pseudomonas aeruginosa to iron: genetics, biochemistry and virulence. Mol Microbiol 1999, 34:399-413.
3. Reid D.W., Withers N.J., Francis L., Wilson J.W., Kotsimbos T.C. Iron deficiency in cystic fibrosis: relationship to lung disease severity and chronic Pseudomonas aeruginosa infection. Chest 2002, 121:48-54.
4. Moreau-Marquis S., Bomberger J.M., Anderson G.G., Swiatecka-Urban A., Ye S., O'Toole G.A., Stanton B.A. The {increment}F508-CFTR mutation results in increased biofilm formation by Pseudomonas aeruginosa by increasing iron availability. Am J Physiol Lung Cell Mol Physiol 2008, 295:L25-L37.
5. O'May C.Y., Sanderson K., Roddam L.F., Kirov S.M., Reid D.W. Iron-binding compounds impair Pseudomonas aeruginosa biofilm formation, especially under anaerobic conditions. J Med Microbiol 2009, 58:765-773.